Safety and Efficacy of Asciminib in Pediatrics and Young Adults With Relapse/Refractory (r/r) Philadelphia Positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
Acute Lymphoblastic Leukemia · Leukemia, Lymphoblastic, Acute, Philadelphia-Positive · Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 50 (planned)
- Started
- Jul 5, 2026
- Main results expected
- Sep 19, 2033
- Fully finished
- May 30, 2036
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Part 1 Dose Escalation: Incidence of Dose Limiting Toxicities (DLTs) occurring during cycle 1 (debulking induction)
Measured over: During Cycle 1 (Cycle 1 = 28 days)
Part 1 Dose Escalation: Incidence and severity of adverse events (AEs) during cycle 1 (debulking induction)
Measured over: During Cycle 1 (Cycle = 28 days)
Part 2 Dose Expansion: Percentage of complete response/remission (CR) evaluable participants who achieve CR treated at recommended phase 2 dose (RP2D) (debulking induction)
Measured over: End of Cycle 1 (Cycle 1 = 28 days)
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07387926 · record last updated 2026-10-15 · checked 2026-11-09 15:47 UTC